Drug screening offers an efficient method by which large numbers of candidate protective drugs can be rapidly identified and evaluated.
Methods for screening potential HC protectants: There are several ways to test the effects of antioxidants on ROS-induced HC damage. 1) In vivo study using animal models is a traditional means of evaluating antioxidant protection. Aminoglycosides, cisplatin or noise are widely used for inducing oxidative stress. A candidate substance which has an antioxidant effect is applied to the cochlea before and after ROS induction. This method has many advantages. First, the intact adult cochlea has all cell types, including both inner and outer HCs as well as cochlear neurons. Second, the adult cochlea is fully functional and hearing can be assessed by auditory brain stem response or distortion product of acoustic emission recordings. Third, histopathological analysis allows for the identification of the exact site of cochlear damage and protection. Fourth, this method has the most direct applicability to the clinical setting. Disadvantages of in vivo testing include potential problems with delivering effective levels of antioxidants to the cochlea. Moreover, testing large numbers of drugs is impractical, time consuming and costly. For these reasons, in vivo testing is often employed to validate results obtained from primary screening. 2) Cochlear cell lines that have characteristics similar to HCs are another means of investigating antioxidant HC protection. HEI-OC1 is one such cell line. These cells express several molecular markers that are characteristic of HCs, are extremely sensitive to ototoxic drugs and grow well in general cell culture conditions (Kalinec et al., 2016) . This in vitro method has the advantage that cell survival can be assessed readily using standard cell viability assays and flow cytometry. Because very large numbers of cells can be generated, many compounds can be evaluated in a high-throughput assay with rapid turnaround. A primary disadvantage of cell lines is that these partially differentiated cells only mimic HCs in part, and do not reflect inner versus outer HCs. Compounds identified in cell lines must be confirmed using in vivo mammalian models.
3) The zebrafish larva has numerous qualities that make it an excellent in vivo whole organism model for HC protection screening. The zebrafish's small size, high fecundity and its optically translucent body make it useful for examining large numbers of treatment conditions and for phenotypic evaluation of HCs. The lateral line HCs are functionally mature. While the lateral line detects the direction and flow rate of water, not auditory stimuli, they operate on the same principal as cochlear HCs and are sensitive to ototoxic drugs. Because large numbers of larvae can be generated, they are consistent with high-throughput screening. Disadvantages of this model are the many differences between lateral line HCs and mammalian cochlear HCs. HCs of the lateral line extend their stereocilia and kinocilia into the surrounding medium, with no separation of ionically distinct fluid spaces analogous to those of the mammalian inner ear. Lateral line HCs do not reflect the properties of inner and outer HCs, and could be considered more similar to vestibular HCs. Thus, discoveries made in zebrafish must be confirmed in vivo mammalian models prior to translational applications (Ou et al., 2012 ).
An in vitro assay based on neonatal micro-explants of the mammalian cochlear sensory epithelium: While no screening assay is ideal, it would be advantageous to be able to screen a larger number of compounds using mammalian HCs with higher throughput than can be accomplished in vivo. We therefore developed an assay based on micro-explants from the basal and middle turns of the neonatal mouse cochlea. To perform the assay, the sensory epithelium is dissected from the cochlea of postnatal day 3-5 pou4f3/eGFP mouse pups. These transgenic animals selectively express eGFP (enhanced green fluorescent protein) in HCs under the control of a pou4f3 promoter construct (Masuda et al., 2011) . The apical region of each epithelium, which is relatively insensitive to aminoglycoside toxicity, is discarded. The basal and middle regions of the epithelium are divided, using a diamond scalpel, into micro-explants consisting of approximately 20 inner HCs and the 60 associated outer HCs (Figure 1) . Micro-explants are individually plated in each well of flat-bottom 96-well plates in media consisting of DMEM/ F-12 (Gibco, Gaithersburg, MD, USA) plus 30 U/mL Penicillin and 5% fetal bovine serum (FBS), maintained in a humidified tissue culture incubator (37°C, 5% CO 2 ).
Each micro-explant is pretreated for 24 hours with one of the candidate compounds at various concentrations, performed in triplicate wells. The following day, the media are withdrawn, fresh media containing 200 µM gentamicin plus the candidate compound at the appropriate concentration is added, and the micro-explants are cultured for 72 hours. GFP-positive HCs are imaged by fluorescence microscopy before the application of gentamicin and then at 1, 2, and 3 days afterward to evaluate HC survival. HC counts, including both inner and outer HCs, are evaluated using ImageJ software (NIH, Bethesda, MD, USA), and normalized as percentages to the number of HCs present on day 1, prior to the start of gentamicin treatment. Any micro-explants that do not attach and flatten in the well by day 1 are excluded (≤ 3% per plate). Gentamicin is used, as opposed to a direct oxidant such as H 2 O 2 , since it is a clinically relevant HC toxin.
Compound "hits" are identified in the initial round of screening as deviating significantly from the control explants treated with gentamicin only. Following this initial identification, repeat plates are prepared in an identical manner for all hits and controls, for a total N of 6 micro-explants/hit compound.
The assay was used to screen a redox compound library (Screen-Well Redox Library, Enzo Life Sciences, Farmingdale, NY, USA) containing 81 antioxidants and 3 pro-oxidants (as controls to provide oxidative stress), as previously reported (Noack et al., 2017) . The results of the screen are illustrated in Figure 2 . It is clear from the figure that only a minority of compounds altered gentamicin-induced HC loss. A total of thirteen antioxidants proved to be protective: seratrodast, idebenone, resveratrol, BHA, BHT, α-lipoic acid, hinokitiol, dithiotreitol, MC186, procysteine, trolox, thiourea and thymoquinone. One pro-oxidant and five anti-oxidants increased HC death. Of note, an additional screen of 160 protein kinase inhibitors that spanned the kinome was also recently performed using this assay (Ryals et al., 2017) .
Advantages and disadvantages of the microexplant assay:
This assay has the advantage that mammalian inner and outer HCs can be evaluated. The outer HC, the most vulnerable element in the mammalian cochlea, is a unique feature that is The percent of hair cells (HCs) initially present in micro-explants exposed to gentamicin alone has been subtracted from that for micro-explants exposed to the compound plus gentamicin. Because antioxidants showed peak protection on different days after the initiation of gentamicin exposure, the highest difference observed either on Day 1, Day 2 or Day 3 of culture is presented. Compounds that proved to provide statistically significant protection after validation are indicated by an asterisk. Most of these compounds showed a protective effect above 25% at 1,000 µM compound concentration. A few (B7 and F7) showed protective effects at lower compound dosages but not at the 1,000 µM concentration illustrated here. Compound identities can be found in the Supplementary Table 1 of Noack et al. (2017) . Data were evaluated by analysis of variance and Fisher's post hoc test with Bonferonni correction for multiple conditions.
* P < 0.05. Change in HC survival (%) with 1,000 µM compound plus gentamicin not present in other classes of animals, such as fish, nor is it modeled in cell lines. Mammalian cochlear HCs thus provide results that may be more applicable to humans. In addition, microexplants allow a much larger number of compounds to be evaluated than could be screened practically in vivo. While the assay is by no means high-throughput, it readily allows the screening of a few hundred compounds. In addition, HC-specific eGFP expression allows continuous monitoring of HC survival throughout the period of the screening assay, instead of a single timepoint snapshot. This eliminates the need for multiple samples to evaluate different times of treatment, as well as the need for HC staining. Finally, because the assay is uniform, it allows not only hit identification, but also information on relative effectiveness between different compounds. Of course, there are also disadvantages to this assay system. Since adult HCs do not survive in culture, the assay is based on neonatal HCs that are not yet functionally mature. As noted, the number of compounds that can be tested is limited compared to cell lines or zebrafish larvae. Similarly, evaluating a very large number of conditions, such as a large range of gentamicin dosages or additional compound concentrations, would be impractical. Finally, as with all screening assays, it does not provide definitive data, but rather identifies candidates that warrant further study. These limitations must be considered when interpreting the results of the assay.
Conclusions: Many experimental studies in animals have
shown that the application of exogenous antioxidants can effectively protect HCs from various forms of damage in vitro and in vivo. In contrast, the results of clinical studies have been more modest or even negative (see Noack et al., 2017 for a review). This may be related to the difficulty of controlling damage to HCs in humans, or insufficient drug delivery to HCs. However, it is also possible that the antioxidants tested were not optimal for HC protection. In vitro screening assays can be used to target in vivo studies, by identifying lead compounds with an increased probability of success. We have developed an efficient and standardized in vitro test with which to screen compounds for their ability to modify the response of mammalian HCs to ototoxins. This can be used to screen larger numbers of antioxidants, as well as a variety of other compound classes suspected of having protective ability. The assay allows the evaluation of multiple compound doses and times of treatment, increasing the chance to detect hits. Given the results presented above, several select antioxidants appear to be attractive candidates for the protection of HCs from the oxidative stress associated with ototoxic drugs and potential noise or aging. These must, of couse, be validated by further study and in vivo testing. In vivo evaluation of the most protedtive antioxidants is planned. It may also be possible to combine these antioxidants with other proteicive compounds, such as those indeitified in our kinase inhibitor screen (Ryals et al., 2017) . DC00139 and VA grant BX001205. 
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